<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942771</url>
  </required_header>
  <id_info>
    <org_study_id>TT301/MW189 Phase 1b</org_study_id>
    <nct_id>NCT02942771</nct_id>
  </id_info>
  <brief_title>A MAD Study of TT301/MW189 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TT301/MW189 Administered Intravenously to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linda Van Eldik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Study is to find out whether an investigational drug is safe and well
      tolerated. MW189 is being studied as a possible short-term treatment for people with
      different types of brain injury. MW189 has previously been given to healthy human volunteers
      as a single dose, and there were no significant problems or bad effects in people who
      received the Study drug. However, before it can be tested in people with brain injury, it is
      important to test MW189 in healthy volunteers when given multiple doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1b study. Written informed consent will be obtained from each study
      participant before any study-specific procedures or assessments are done.

      At various time points noted below, pharmacokinetic (PK) blood sampling will be performed on
      study participants.

      Throughout the study the investigator will be assessing adverse events and concomitant
      medication.

      On-Study/On-Interventions Evaluations/procedures: Participants will arrive at the Phase 1
      unit after fasting a minimum of 10 hours, for admission into the unit and will undergo
      procedures:

        -  Medical and medication histories

        -  Infection screen

        -  Body temperature

        -  Vital signs (blood pressure and heart rate)

        -  Physical examination and weight

        -  Neurological exam

        -  Safety laboratory tests (blood and urine)

        -  Urine pregnancy test (females only)

        -  Alcohol screening (Breathalyzer)

        -  Urine drug screen

        -  Hepatitis B, C and HIV screening

        -  Randomize: Only participants who meet eligibility requirements will be randomized into
           the study.

      Day 1 - Dosing: A light breakfast will be given prior to dosing. Participants will have the
      following tests/procedures performed at various time points during the day following
      confirmation of eligibility.

        -  8 electrocardiograms (ECG)

        -  8 vital signs (blood pressure and heart rate)

        -  1 body temperature

        -  12 PK Blood draws

        -  2 study drug administrations

      Day 2: A light breakfast will be given prior to dosing.

        -  8 ECGs

        -  8 vital signs (blood pressure and heart rate)

        -  1 body temperature

        -  1 PK blood draw

        -  2 study Drug administration

      Day 3: Participants will fast for a minimum of 10 hours. Water is allowed. A Light breakfast
      will be given before dosing

        -  1 safety laboratory tests (blood and urine)

        -  1 ECG

        -  2 vital signs (blood pressure and heart rate)

        -  1 body temperature

        -  1 PK blood draw

        -  1 neurological examination

        -  2 study drug administrations

      Day 4: A Light breakfast will be given before dosing

        -  2 vital signs (blood Pressure and heart rate)

        -  1 body temperature

        -  1 PK blood draw

        -  2 study drug administrations

      Day 5: A Light breakfast will be given before dosing

        -  1 ECG

        -  2 vital signs (Blood Pressure and heart rate)

        -  1 body temperature

        -  12 PK blood draw

        -  2 study drug administration

      Day 6: Participants will fast for a minimum of 10 hours. Water is allowed. A Light breakfast
      will be given

        -  1 safety laboratory test (blood and urine)

        -  1 vital sign (Blood pressure and heart rate)

        -  1 body temperature

        -  1 neurological examination

        -  2 PK blood draw

      Day 7: A light breakfast will be provided

        -  1 vital sign

        -  1 body temperature

        -  1 PK blood draw

      Day 8 (Discharge): Participants will fast for a minimum of 10 hours. Water is allowed. A
      light breakfast will be offered

        -  1 safety laboratory test (blood and urine)

        -  1 ECG

        -  1 vital sign (blood pressure and heart rate)

        -  1 body temperature

        -  1 physical examination including weight

        -  1 neurological examination

           2 Week Follow-up Visit: Participants will fast for a minimum of 10 hours. Water is
           allowed.

      during this visit participants will have the following tests and procedures performed:

        -  1 safety laboratory test (blood and urine)

        -  1 ECG

        -  1 vital sign (blood pressure and heart rate)

        -  1 body temperature

      6-8 Week Follow-up Phone Call: Participants will be asked about any adverse events and any
      medications they may be taking.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Actual">June 4, 2018</completion_date>
  <primary_completion_date type="Actual">June 4, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of participants who experienced serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>The number of participants who experienced treatment-emergent adverse events (TEAEs). A TEAE is defined as an adverse event that started during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Cmax</measure>
    <time_frame>5 days</time_frame>
    <description>Maximum observed concentration in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Tmax</measure>
    <time_frame>5 days</time_frame>
    <description>Time to maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - AUC</measure>
    <time_frame>5 days</time_frame>
    <description>Area under the concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - T1/2</measure>
    <time_frame>5 days</time_frame>
    <description>Terminal half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Kel</measure>
    <time_frame>5 days</time_frame>
    <description>Elimination rate constant</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - TT301/MW189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 -TT301/MW189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3- TT301/MW189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4- TT301/MW189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No drug intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075mg/kg TT301/MW189</intervention_name>
    <description>0.075 mg/kg IV twice daily on Days 1 through 5</description>
    <arm_group_label>Cohort 1 - TT301/MW189</arm_group_label>
    <other_name>TT301/MW189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.15mg/kg TT301MW189</intervention_name>
    <description>0.15 mg/kg IV twice daily on Days 1 through 5</description>
    <arm_group_label>Cohort 2 -TT301/MW189</arm_group_label>
    <other_name>TT301/MW189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25mg/kg TT301/MW189</intervention_name>
    <description>0.25 mg/kg IV twice daily on Days 1 through 5</description>
    <arm_group_label>Cohort 3- TT301/MW189</arm_group_label>
    <other_name>TT301/MW189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.30mg/kg TT301/MW189</intervention_name>
    <description>0.30 mg/kg IV twice daily on Days 1 through 5</description>
    <arm_group_label>Cohort 4- TT301/MW189</arm_group_label>
    <other_name>TT301/MW189</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness and capacity to give informed consent

          -  Is in good health

          -  Weights 50.0 - 120.0 kg

          -  Not pregnant

          -  Must agree to use birth control for 1 week after the last day of study drug
             administration

          -  Willingness to comply with protocol requirements, including fasting, alcohol and
             nicotine restrictions, during the study and is available to complete the study

          -  Adequate forearm vein access

          -  No significant dietary restrictions

          -  Must not have donated blood, platelets, or any other blood components 30 days, or
             plasma 60 days, prior to consenting. Must also agree not to donate blood, platelets,
             or any other blood components for 8 weeks after the last dose of study drug

        Exclusion Criteria:

          -  Lactating or is pregnant

          -  severe ischemic heart disease or congestive heart failure

          -  Heart attack within the previous 2 years;

          -  history of stroke or cardiomyopathy;

          -  significant liver or kidney disease;

          -  diabetes;

          -  history of any autoimmune disorder; or a history of chronic infections

          -  a history of cancer

          -  has received antibiotic treatment or has undergone a surgical procedure within 30 days
             of Day 1

          -  has a history of Hepatitis C, Hepatitis B or tuberculosis (TB)

          -  has a history of Human Immunodeficiency Virus (HIV)

          -  a history of alcohol or drug use within the twelve months prior to study drug
             administration

          -  has used any immunosuppressants or chronic anti-inflammatory drugs medication
             including prescription medication, over-the-counter medication, health/herbal
             supplement or vitamin by any route of administration within 7 days of Day 1

          -  has donated blood within 30 days of consenting or has donated plasma within 60 days of
             consenting

          -  has participated in a clinical trial of an immunosuppressive drug within 6 months of
             Day 1

          -  has received an investigational drug, used an investigational device or received an
             investigational medical procedure within 60 days of Day 1, or concurrent with
             participation in this study

          -  has participated in any observational studies, experimental studies of
             non-investigational drugs, devices, or medical procedures within 30 days of Day 1, or
             concurrent with participation in this study

          -  has participated in a previous trial with TT301/MW189

          -  has a history of unexplained syncope or fainting from the collection of blood; i.e.,
             autonomic dysfunction.

          -  Lack of ability to understand verbal and/ or written English

          -  had significant trauma or surgical procedure within 1 month prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda J. Van Eldik, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey T. Guptill, MD, MA,MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Unit 40 Duke Medicine Circle</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Van Eldik LJ, Sawaki L, Bowen K, Laskowitz DT, Noveck RJ, Hauser B, Jordan L, Spears TG, Wu H, Watt K, Raja S, Roy SM, Watterson DM, Guptill JT. First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Clin Pharmacol Drug Dev. 2020 Apr 7. doi: 10.1002/cpdd.795. [Epub ahead of print]</citation>
    <PMID>32255549</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>May 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Linda Van Eldik</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02942771/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1 - TT301/MW189</title>
          <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2 -TT301/MW189</title>
          <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3- TT301/MW189</title>
          <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="P5">
          <title>Cohort 4- TT301/MW189</title>
          <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject who was enrolled and assigned to the placebo arm was withdrawn from the study prior to beginning the intervention. This subject is excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1 - TT301/MW189</title>
          <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2 -TT301/MW189</title>
          <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3- TT301/MW189</title>
          <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="B5">
          <title>Cohort 4- TT301/MW189</title>
          <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" spread="6.7"/>
                    <measurement group_id="B2" value="32.4" spread="5.9"/>
                    <measurement group_id="B3" value="31.6" spread="6.2"/>
                    <measurement group_id="B4" value="34.5" spread="7.4"/>
                    <measurement group_id="B5" value="30.5" spread="10.9"/>
                    <measurement group_id="B6" value="33.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165.8" spread="6.7"/>
                    <measurement group_id="B2" value="171.6" spread="8.7"/>
                    <measurement group_id="B3" value="164.0" spread="11.1"/>
                    <measurement group_id="B4" value="170.9" spread="10.5"/>
                    <measurement group_id="B5" value="173.1" spread="8.4"/>
                    <measurement group_id="B6" value="169.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.5" spread="6.1"/>
                    <measurement group_id="B2" value="70.5" spread="9.1"/>
                    <measurement group_id="B3" value="75.2" spread="6.3"/>
                    <measurement group_id="B4" value="85.5" spread="20.5"/>
                    <measurement group_id="B5" value="86.4" spread="12.7"/>
                    <measurement group_id="B6" value="78.6" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="1.9"/>
                    <measurement group_id="B2" value="24.1" spread="3.8"/>
                    <measurement group_id="B3" value="28.1" spread="2.7"/>
                    <measurement group_id="B4" value="29.1" spread="5.7"/>
                    <measurement group_id="B5" value="28.8" spread="3.8"/>
                    <measurement group_id="B6" value="27.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Adverse Events</title>
        <description>The number of participants who experienced serious adverse events.</description>
        <time_frame>4 weeks</time_frame>
        <population>One subject randomized to the Placebo Group was withdrawn prior to receiving the study drug. Consequently, this subject is excluded from this safety analysis. As the remaining 8 subjects in the Placebo Group and all 8 subjects in Cohort 4 received an intervention they are included in safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>The number of participants who experienced serious adverse events.</description>
          <population>One subject randomized to the Placebo Group was withdrawn prior to receiving the study drug. Consequently, this subject is excluded from this safety analysis. As the remaining 8 subjects in the Placebo Group and all 8 subjects in Cohort 4 received an intervention they are included in safety outcomes.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Treatment-Emergent Adverse Events</title>
        <description>The number of participants who experienced treatment-emergent adverse events (TEAEs). A TEAE is defined as an adverse event that started during the treatment period.</description>
        <time_frame>4 weeks</time_frame>
        <population>One subject randomized to the Placebo Group was withdrawn prior to receiving the study drug. Consequently, this subject is excluded from this safety analysis. As the remaining 8 subjects in the Placebo Group and all 8 subjects in Cohort 4 received an intervention they are included in safety outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent Adverse Events</title>
          <description>The number of participants who experienced treatment-emergent adverse events (TEAEs). A TEAE is defined as an adverse event that started during the treatment period.</description>
          <population>One subject randomized to the Placebo Group was withdrawn prior to receiving the study drug. Consequently, this subject is excluded from this safety analysis. As the remaining 8 subjects in the Placebo Group and all 8 subjects in Cohort 4 received an intervention they are included in safety outcomes.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Cmax</title>
        <description>Maximum observed concentration in plasma.</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Cmax</title>
          <description>Maximum observed concentration in plasma.</description>
          <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="227" spread="80.5"/>
                    <measurement group_id="O3" value="347" spread="86.8"/>
                    <measurement group_id="O4" value="609" spread="180"/>
                    <measurement group_id="O5" value="750" spread="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Tmax</title>
        <description>Time to maximum concentration</description>
        <time_frame>5 days</time_frame>
        <population>Tmax was not measured for any group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Tmax</title>
          <description>Time to maximum concentration</description>
          <population>Tmax was not measured for any group.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - AUC</title>
        <description>Area under the concentration-time curve</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - AUC</title>
          <description>Area under the concentration-time curve</description>
          <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="362" spread="123"/>
                    <measurement group_id="O3" value="639" spread="220"/>
                    <measurement group_id="O4" value="1225" spread="474"/>
                    <measurement group_id="O5" value="1525" spread="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - T1/2</title>
        <description>Terminal half-life (T1/2)</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - T1/2</title>
          <description>Terminal half-life (T1/2)</description>
          <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.5" spread="3.4"/>
                    <measurement group_id="O3" value="8.5" spread="3.7"/>
                    <measurement group_id="O4" value="8.8" spread="2.8"/>
                    <measurement group_id="O5" value="9.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics - Kel</title>
        <description>Elimination rate constant</description>
        <time_frame>5 days</time_frame>
        <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - TT301/MW189</title>
            <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 -TT301/MW189</title>
            <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3- TT301/MW189</title>
            <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
          <group group_id="O5">
            <title>Cohort 4- TT301/MW189</title>
            <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics - Kel</title>
          <description>Elimination rate constant</description>
          <population>Pharmacokinetic parameters for TT301/MW189 can not be analyzed in the placebo group, as they did not receive the study drug. Although 8 subjects were enrolled in Cohort 4 and are included in the safety analyses, only 4 completed sampling for PK parameters at all timepoints.</population>
          <units>h^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.090" spread="0.029"/>
                    <measurement group_id="O3" value="0.093" spread="0.034"/>
                    <measurement group_id="O4" value="0.085" spread="0.028"/>
                    <measurement group_id="O5" value="0.081" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Assessment was systematic. Safety and tolerability were assessed by clinical observation, lab tests and spontaneous reporting by subjects. Placebo group: 9 subjects were randomized,1 subject withdrew prior to starting the intervention. As this subject did not receive intervention, safety data are reported only for the remaining 8 subjects. Cohort 4: 8 subjects were randomized, only 4 completed all timepoints. As all 8 subjects received study drug, safety data are reported for all 8.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>No drug intervention.
Placebo: 0.9% sodium chloride</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 - TT301/MW189</title>
          <description>TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 1 - TT301/MW189: 0.075 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 -TT301/MW189</title>
          <description>TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 2- TT301MW189: 0.15 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3- TT301/MW189</title>
          <description>TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 3 - TT301/MW189: 0.25 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
        <group group_id="E5">
          <title>Cohort 4- TT301/MW189</title>
          <description>TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
Cohort 4 - TT301/MW189: 0.30 mg/kg IV twice daily on Days 1 through 5</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Abdominal Pain, Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sensitivity of Teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion-Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion-Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion-Site Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG T-Wave Inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased Blood Creatine Phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Decreased Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Parasthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contact Dermatitits</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diastolic Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Linda Van Eldik</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>(859) 257-5566</phone>
      <email>linda.vaneldik@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

